Effects of epinephrine or tramazoline on nasal bleeding during nasal intubation - Effects of epinephrine or tramazoline on nasal bleeding during nasal intubation

Start Date16 Sep 2019

Sponsor / Collaborator-

NCT01601509 / CompletedNot ApplicableIIT

Randomized Placebo-controlled Cross-over Trial of the Effect of Nasal Tramazoline With Dexamethasone in Obstructive Sleep Apnoea Patients

Nasal resistance presents considerable variations during night[8]. Additionally, Oral and oro-nasal breathing epochs exhibit strong correlation with the number of apnoea/hypopnoeas [7].The hypothesis that the present study aims to test is whether the pharmacological prevention of increased nasal resistance during night could alter breathing route pattern and lead to a decrease in the number of apnoea/hypopnoeas in OSA patients with normal nasal resistance.

Start Date01 Apr 2010

Sponsor / Collaborator

National & Kapodistrian University of Athens

100 Clinical Results associated with Tramazoline Hydrochloride

100 Translational Medicine associated with Tramazoline Hydrochloride

100 Patents (Medical) associated with Tramazoline Hydrochloride

Literatures (Medical) associated with Tramazoline Hydrochloride

01 Dec 2021·BMC AnesthesiologyQ4 · MEDICINE

Comparison of hemostatic effect and safety between epinephrine and tramazoline during nasotracheal intubation: a double-blind randomized trial

Q4 · MEDICINE

ArticleOA

Author: Sobue, Kazuya ; Kamimura, Yuji ; Hoshijima, Hiroshi ; Kako, Eisuke ; Tachi, Naoko ; Hashimoto, Mayumi ; Okuda, Masahiro ; Sato-Boku, Aiji ; Suzuki, Fumihito ; Sento, Yoshiki ; Okumura, Yoko

AbstractBackgroundNasal bleeding is the most common complication during nasotracheal intubation (NTI). To reduce nasal bleeding, the nasal mucosa is treated with vasoconstrictors (epinephrine [E] or tramazoline [T]) prior to NTI. This study aimed to determine whether E or T is more effective and safe for reducing nasal bleeding during NTI.MethodsThis study was preregistered on UMIN-CTR after being approved by the IRB of the School of Dentistry at Aichi Gakuin University. Written consent was received from all the patients. Total 206 patients aged 20–70 years and classified as 1–2 on American Society of Anesthesiologists-physical status were scheduled to undergo general anesthesia with NTI. At last, 197 patients were randomly divided into two groups and treated with either E (n = 99; 3 patients were discontinued) or T (n = 98; 2 patient were discontinued). After induction of general anesthesia, each patient’s nasal mucosa was treated using either E or T. The E used in this study was BOSMIN® SOLUTION 0.1% (Daiichi-Sankyo Co., Ltd., Tokyo), and the T used in this study was TRAMAZOLIN Nasal Solution 0.118% AFP, (Alfresa Pharma Corporation, Osaka). E was diluted five times according to the package insert (final concentration of E = 0.02%), and T was used in its original solution. After 2 min, NTI was performed via the right nostril. Primary outcome were the presence of nasal bleeding (if bleeding was recognized at the posterior pharyngeal wall via nasal cavity during intubation, it was defined as bleeding) and the degree of bleeding (classified as none, mild, moderate, or severe). Secondary outcomes were arrhythmia, and hemodynamic (mean atrial pressure and heart rate) changes associated with vasoconstrictors.ResultsThe presence of bleeding was comparable in both groups (12.5%, E; 14.5%, T; P = 0.63). No significant difference between the groups regarding the degree of bleeding (P = 0.78) was observed, with most patients having no bleeding (n = 84, E; n = 82, T). No severe bleeding and no arrhythmias induced by vasoconstrictor were observed in the two groups.ConclusionsNasal treatment with E or T shows no difference in nasal bleeding during NTI. Although no arrhythmia associated with E was observed in this study, it has been reported in literature. Therefore, as frequency and degree of nasal bleeding were comparable, nasal treatment with T could reduce the risk of NTI.Trial registrationUMIN-CTR (Registration No. UMIN000037907). Registered (05/09/2019).

01 Aug 2019·Sleep Medicine ReviewsQ1 · MEDICINE

Efficacy of pharmacotherapy for OSA in adults: A systematic review and network meta-analysis

Q1 · MEDICINE

Review

Author: Gaisl, Thomas ; Kohler, Malcolm ; Thiel, Sira ; Osswald, Martin ; Haile, Sarah R

Pharmacotherapy represents a desirable potential therapeutic alternative for patients with obstructive sleep apnoea (OSA). We aimed to summarize evidence on the efficacy of pharmacotherapy in adults with OSA and delineate the underlying mechanisms. Seven databases were systematically screened for randomised controlled trials (RCTs) from their inception to September 2018. According to a pre-registered study protocol (PROSPERO-ID-CRD42018086446) network meta-analysis was performed to obtain intervention effects on the apnoea-hypopnoea-index (AHI) based on data extracted from published reports. We identified 58 RCTs (n = 1710 patients) investigating 44 different drugs or drug-combinations. Interventions were classified into seven pathomechanism-groups and summarized narratively. A meta-analysis of 17 trials for seven drugs (acetazolamide, donepezil, mirtazapine, ondansetron, paroxetine, protriptyline, theophylline) indicated a small effect for acetazolamide (mean difference in AHI -9.6/h [-17.7; -1.4]; p = 0.02). In the network meta-analysis (I² = 50%) nine drugs (tramazoline, liraglutide, spironolactone/furosemide, acetazolamide, dronabinol, zonisamide, phentermine, spironolactone, and ondansetron/fluoxetine) significantly lowered the AHI compared to placebo. Although some trials indicate favorable outcomes, these results are only valid for distinctive OSA-phenotypes or were not clinically significant. The effect sizes were small, the majority of trials were not adequately powered. There is currently insufficient evidence to recommend any pharmacotherapy for OSA and no phase-III trials are available.

01 Jan 2015·Clinical and Translational AllergyQ2 · MEDICINE

Treatment of acute rhinitis with a nasal spray containing tramazoline and essential oils: a multicenter, uncontrolled, observational trial

Q2 · MEDICINE

ArticleOA

Author: Simon, Ákos ; Láng, Júlia ; Fülöp, Gabriella ; Radvánszky, Ferenc ; Sultész, Mónika ; Hirschberg, Andor ; Holm, Claudia ; Gyimesi, Andrea ; Nirnberger, Günther ; Katona, Gábor ; Huszka, János ; Farkas, Zsolt ; Ablonczy, Mária

AbstractBackgroundIn this observational trial, data were collected on the effectiveness and tolerability/safety of a nasal spray containing tramazoline and essential oils (trade name Rhinospray® Plus) used for symptomatic treatment of acute rhinitis due to common cold.MethodsThe trial was performed in 300 children, adolescents and adults, who were to be treated with Rhinospray® Plus for up to 4 times per day for up to 10 days. Primary endpoints were the change from baseline to final visit in the mean of three single symptom scores (blocked nose, sneezing, and runny nose) and the mean improvement in two quality‐of‐life parameters (ability to perform normal daytime activities and quality of sleep).ResultsA total of 108 children, 30 adolescents and 162 adults were treated with Rhinospray® Plus. No patient discontinued prematurely. There was a mean reduction of 2.0 ± 0.6 (standard deviation) in nasal symptom scores from baseline to final visit; 297 of 300 of patients (99.0 %) reported an improvement. The mean value for improvement in quality‐of‐life parameters was 1.3 ± 0.5. Improvement in daytime activities was reported by all 300 patients (100.0 %) and in quality of sleep by 292 patients (97.4 %). Effectiveness and tolerability were rated as ‘very good’ or ‘good’ by 95.4 % and 97.4 % of patients, respectively; the investigators rated effectiveness and tolerability as ‘very good’ or ‘good’ for 97.4 % and 100.0 % of patients, respectively. No adverse events were reported.ConclusionsCommunity‐based patients reported a relief in acute rhinitis symptoms and improvement in quality of life as a result of treatment with Rhinospray® Plus. Treatment was well‐tolerated.

100 Deals associated with Tramazoline Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01347	Tramazoline Hydrochloride	R01AA09	DB13064

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Nasal Obstruction	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01601509 (Pubmed \| Clin Chest Med)	Not Applicable	Sleep Apnea, Obstructive	21	Nasal tramazoline with dexamethasone	emoecuuxec(etthhbazgs) = gjwjigjwwr kbygrndgwr (xdkdaouino )	Positive	01 Oct 2013

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis